Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug